Agile Initiated With A Buy At Janney Capital; Considers AGRX A Compelling Investment
Janney Capital analyst Kimberly Lee is out today with an interesting call initiating Agile Therapeutics, Inc. (AGRX) with a Buy rating and $18 fair value estimate.
“We view Agile’s main value driver, Twirla (AG200-15), as a validated, combined hormonal contraceptive (CHC) patch that should improve patient compliance and provide efficacy and safety similar to low-dose oral contraceptives while targeting an unmet need for a patch contraceptive option. Its value proposition lies in its once-weekly delivery of low-dose estrogen via a proprietary transdermal patch technology, which does not carry the additional safety risks associated with higher estrogen levels. AGRX’s near-term success will be correlated with a successful Phase 3 study outcome and is fairly de-risked, in our view, given several recent contraceptive approvals along with the additional clarity received from the FDA on study design following a Complete Response Letter (CRL). We estimate that Twirla does not need to garner significant market share in the $4.2 billion CHC market to become a blockbuster product and we estimate peak sales of $1.0 billion under conservative assumptions. We consider AGRX a compelling investment based on its proprietary transdermal technology, its differentiated and burgeoning pipeline, experienced management team and attractive valuation”, wrote Kimberly.
According to TipRanks, which measures analysts and bloggers success rate based on how their calls perform, analyst Kimberly Lee, who covers AGRX, currently has a one-year average return of 18.3% and a 50% success rate, and ranked #977 out of 3104 analysts.